Dental Biomaterials Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Dental Biomaterials Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)


Dental biomaterials, widely used for the treatment of fractures, decay, and injuries in the oral cavity, are gaining momentum as a crucial component of modern dentistry. These biomaterials not only replace damaged teeth but also facilitate tissue repair, contributing to their increasing adoption. With a rise in dental problems worldwide, the Global Dental Biomaterials Market is set to exhibit significant growth.

The global dental biomaterials market is set to experience substantial growth over the next decade. By 2031, the global Dental Biomaterials Market is anticipated to exceed a valuation of $2.2 billion.

Key Drivers of the Dental Biomaterials Market

Increasing Prevalence of Oral Disorders: The surging prevalence of oral disorders, including periodontal disease, tooth decay, oral cancer, halitosis, and dental caries, among others, is a prominent driver of market growth. Patients grappling with oral health issues are undergoing various elective procedures, spurring the demand for dental biomaterials. These biomaterials, recognized for their promising results and high success rates in oral treatment and prevention, are poised to drive the global dental biomaterials market.

Increased Awareness and Disposable Income: The growing awareness about the significance of dental implants, particularly in middle and low-income countries, is expected to bolster market growth. Furthermore, the rise in disposable income in developed nations has led to an increased demand for aesthetic treatments such as teeth whitening and gum contouring. This trend is set to fuel market expansion throughout the forecast period.

Restraints to the Dental Biomaterials Market

High Cost of Procedures and Lack of Skilled Dental Professionals: Dental procedures are often cost-prohibitive due to the expensive dental biomaterials and equipment involved, making them inaccessible to many individuals in middle and low-income nations. Additionally, dental procedures necessitate highly skilled dental professionals, and there is a global shortage of such experts. The lengthy clinical procedures and stringent regulatory approvals for innovative dental biomaterials can also impede market growth in the forecast period.

Competitive Landscape

The Dental Biomaterials Market exhibits moderate competitiveness, with a presence of both domestic and international players. Global leaders dominate the market, while emerging players are adopting innovative strategies, both organic and inorganic, to expand their product footprint in the global dental biomaterials market.

Key Companies Profiled:
• Geistlich Pharma, Inc.
• Zimmer Biomet
• 3M Company
• Dentsply Sirona
• Institut Straumann AG
• Danaher Corporation (Nobel Biocare Services AG)
• Others

Dental Biomaterials Market Categorization

Dental Biomaterials Market by End User
• Hospitals
• Dental Clinics
• Others

Dental Biomaterials Market by Product Type
• Dental Membranes
• Dental Bone Graft Substitutes
• Dental Materials

Dental Biomaterials Market by Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.


1. Executive Summary
1.1. Global Clostridium Difficile Infection Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Clostridium Difficile Infection Treatment Market Outlook, 2018 – 2031
3.1. Global Clostridium Difficile Infection Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 – 2031
3.1.1. Key Highlights
3.1.1.1. Metronidazole
3.1.1.2. Vancomycin
3.1.1.3. Fidaxomicin
3.2. Global Clostridium Difficile Infection Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
3.2.1. Key Highlights
3.2.1.1. Oral
3.2.1.2. Injectable
3.3. Global Clostridium Difficile Infection Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacies
3.3.1.2. Retail Pharmacies
3.3.1.3. Mail Order Pharmacies
3.4. Global Clostridium Difficile Infection Treatment Market Outlook, by Region, Value (US$ Bn), 2018 – 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Clostridium Difficile Infection Treatment Market Outlook, 2018 – 2031
4.1. North America Clostridium Difficile Infection Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 – 2031
4.1.1. Key Highlights
4.1.1.1. Metronidazole
4.1.1.2. Vancomycin
4.1.1.3. Fidaxomicin
4.2. North America Clostridium Difficile Infection Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
4.2.1. Key Highlights
4.2.1.1. Oral
4.2.1.2. Injectable
4.3. North America Clostridium Difficile Infection Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacies
4.3.1.2. Retail Pharmacies
4.3.1.3. Mail Order Pharmacies
4.4. North America Clostridium Difficile Infection Treatment Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
4.4.1.2. U.S. Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
4.4.1.3. U.S. Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
4.4.1.4. Canada Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
4.4.1.5. Canada Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
4.4.1.6. Canada Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Clostridium Difficile Infection Treatment Market Outlook, 2018 – 2031
5.1. Europe Clostridium Difficile Infection Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 – 2031
5.1.1. Key Highlights
5.1.1.1. Metronidazole
5.1.1.2. Vancomycin
5.1.1.3. Fidaxomicin
5.2. Europe Clostridium Difficile Infection Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
5.2.1. Key Highlights
5.2.1.1. Oral
5.2.1.2. Injectable
5.3. Europe Clostridium Difficile Infection Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Retail Pharmacies
5.3.1.3. Mail Order Pharmacies
5.4. Europe Clostridium Difficile Infection Treatment Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
5.4.1. Key Highlights
5.4.1.1. Germany Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
5.4.1.2. Germany Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
5.4.1.3. Germany Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.4. U.K. Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
5.4.1.5. U.K. Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
5.4.1.6. U.K. Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.7. France Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
5.4.1.8. France Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
5.4.1.9. France Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.10. Italy Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
5.4.1.11. Italy Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
5.4.1.12. Italy Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.13. Turkey Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
5.4.1.14. Turkey Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
5.4.1.15. Turkey Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.16. Russia Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
5.4.1.17. Russia Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
5.4.1.18. Russia Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.19. Rest of Europe Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
5.4.1.20. Rest of Europe Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
5.4.1.21. Rest of Europe Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Clostridium Difficile Infection Treatment Market Outlook, 2018 – 2031
6.1. Asia Pacific Clostridium Difficile Infection Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 – 2031
6.1.1. Key Highlights
6.1.1.1. Metronidazole
6.1.1.2. Vancomycin
6.1.1.3. Fidaxomicin
6.2. Asia Pacific Clostridium Difficile Infection Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
6.2.1. Key Highlights
6.2.1.1. Oral
6.2.1.2. Injectable
6.3. Asia Pacific Clostridium Difficile Infection Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Retail Pharmacies
6.3.1.3. Mail Order Pharmacies
6.4. Asia Pacific Clostridium Difficile Infection Treatment Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
6.4.1. Key Highlights
6.4.1.1. China Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
6.4.1.2. China Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
6.4.1.3. China Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.1.4. Japan Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
6.4.1.5. Japan Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
6.4.1.6. Japan Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.1.7. South Korea Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
6.4.1.8. South Korea Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
6.4.1.9. South Korea Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.1.10. India Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
6.4.1.11. India Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
6.4.1.12. India Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.1.13. Southeast Asia Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
6.4.1.14. Southeast Asia Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
6.4.1.15. Southeast Asia Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.1.16. Rest of Asia Pacific Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
6.4.1.17. Rest of Asia Pacific Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
6.4.1.18. Rest of Asia Pacific Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Clostridium Difficile Infection Treatment Market Outlook, 2018 – 2031
7.1. Latin America Clostridium Difficile Infection Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 – 2031
7.1.1. Key Highlights
7.1.1.1. Metronidazole
7.1.1.2. Vancomycin
7.1.1.3. Fidaxomicin
7.2. Latin America Clostridium Difficile Infection Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
7.2.1. Key Highlights
7.2.1.1. Oral
7.2.1.2. Injectable
7.3. Latin America Clostridium Difficile Infection Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Retail Pharmacies
7.3.1.3. Mail Order Pharmacies
7.4. Latin America Clostridium Difficile Infection Treatment Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
7.4.1.2. Brazil Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
7.4.1.3. Brazil Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
7.4.1.4. Mexico Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
7.4.1.5. Mexico Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
7.4.1.6. Mexico Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
7.4.1.7. Argentina Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
7.4.1.8. Argentina Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
7.4.1.9. Argentina Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
7.4.1.10. Rest of Latin America Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
7.4.1.11. Rest of Latin America Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
7.4.1.12. Rest of Latin America Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Clostridium Difficile Infection Treatment Market Outlook, 2018 – 2031
8.1. Middle East & Africa Clostridium Difficile Infection Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 – 2031
8.1.1. Key Highlights
8.1.1.1. Metronidazole
8.1.1.2. Vancomycin
8.1.1.3. Fidaxomicin
8.2. Middle East & Africa Clostridium Difficile Infection Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
8.2.1. Key Highlights
8.2.1.1. Oral
8.2.1.2. Injectable
8.3. Middle East & Africa Clostridium Difficile Infection Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Retail Pharmacies
8.3.1.3. Mail Order Pharmacies
8.4. Middle East & Africa Clostridium Difficile Infection Treatment Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
8.4.1. Key Highlights
8.4.1.1. GCC Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
8.4.1.2. GCC Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
8.4.1.3. GCC Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.4.1.4. South Africa Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
8.4.1.5. South Africa Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
8.4.1.6. South Africa Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.4.1.7. Egypt Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
8.4.1.8. Egypt Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
8.4.1.9. Egypt Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.4.1.10. Nigeria Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
8.4.1.11. Nigeria Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
8.4.1.12. Nigeria Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.4.1.13. Rest of Middle East & Africa Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2018 – 2031
8.4.1.14. Rest of Middle East & Africa Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2018 – 2031
8.4.1.15. Rest of Middle East & Africa Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Drug Type vs Route of Administration Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Merck & Co., Inc
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Baxter International Inc.
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Sanofi S.A.
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Pfizer Inc.
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Novartis AG
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Astellas Pharma
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Eli LilIy & Company
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. AstraZeneca
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Actelion Pharmaceuticals Ltd (Sub. of Johnson & Johnson Services, Inc.)
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Mylan N.V.
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings